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1. INTRODUCTION {#mgg31442-sec-0005}
===============

In late December of 2019, a novel coronavirus was found in Wuhan (Chen et al., [2020](#mgg31442-bib-0005){ref-type="ref"}), causing an epidemic outbreak of novel coronavirus‐induced pneumonia with dramatically increasing number of cases, 76,396 confirmed and 2,348 fatalities in China till 22nd February (She et al., [2020](#mgg31442-bib-0025){ref-type="ref"}). It has been reported that there was 82% similarity of genome sequence between the SARS‐CoV and the novel coronavirus, which was named after SARS‐Cov‐2 by WHO (Chan et al., [2020](#mgg31442-bib-0003){ref-type="ref"}; Van de Werf et al., [2012](#mgg31442-bib-0027){ref-type="ref"}). This theory might indicate that SARS‐Cov‐2 infected human being via the same pathway as SARS‐CoV, *ACE2* (OMIM \# 300335), and using cellular protease *TMPRSS2* (OMIM \#602060) for priming (Hoffmann et al., [2020](#mgg31442-bib-0010){ref-type="ref"}).

Apart from acute respiratory distress syndrome (ARDS) due to lung infection, other organs were revealed the potential risk of different human organs vulnerable to SARS‐Cov‐2 infection, such as lung, heart, digestive tract, and male reproductive system (Chai et al., [2020](#mgg31442-bib-0002){ref-type="ref"}; Wang & Xu, [2020](#mgg31442-bib-0029){ref-type="ref"}; Zhang et al., [2020](#mgg31442-bib-0033){ref-type="ref"}; Zou et al., [2020](#mgg31442-bib-0034){ref-type="ref"}). From a recent 138 hospitalized patients' study, five acute kidney injury (AKI) (5/138, 3.6%) cases were reported, which might be caused by entry of SARS‐Cov‐2 through *ACE2* receptor resulting in kidney injury (Wang et al., [2020](#mgg31442-bib-0028){ref-type="ref"}). Although previous studies (Mizuiri & Ohashi, [2015](#mgg31442-bib-0016){ref-type="ref"}) had reported *ACE2* is expressed mainly in proximal tubules and glomeruli with the function of synthesis of inactive angiotensin 1--9 (Ang 1--9) from Angiotensin I (Ang I) and catabolism of Ang II to produce angiotensin 1--7 (And 1--7), which reduces vasoconstriction, water retention, salt intake, cell proliferation, reactive oxygen stress, and renoprotective effect. However, as the functional complexity of these structures appears to be associated with different cell types, the expression level, and function of *ACE2* in different cell types of human kidney is still unclear.

According to the study reporting kidney injury cases, direct effect of virus was suspected (Wang et al., [2020](#mgg31442-bib-0028){ref-type="ref"}), and Academician Nanshan, Zhong, leader of high‐level steering team dealing with outbreak of COVID‐19 in China, declared that virus of COVID‐19, SARS‐Cov‐2, was separated from patients' urine sample (Le, Knoedler, & Roberge, [2020](#mgg31442-bib-0012){ref-type="ref"}). However, the potential route of SARS‐Cov‐2 entry and mechanism of kidney injury base on cellular level is unclear. Consequently, we hypothesize that SARS‐Cov‐2 may enter kidney by ACE2‐related pathway leading kidney injury. In this study, based on public databases, single‐cell RNA sequencing (scRNA‐seq) technology was used to obtain evidences of potential route of SARS‐Cov‐2 entry and underlying pathogenesis of kidney injury in COVID‐19 patients.

2. MATERIALS AND METHODS {#mgg31442-sec-0006}
========================

2.1. Ethical compliance {#mgg31442-sec-0007}
-----------------------

This study does not include any participant or animal subjects so that the ethical compliance is not applicable.

2.2. Data sources {#mgg31442-sec-0008}
-----------------

Gene expression matrix of normal human kidney were obtained from Gene Expression Omnibus (<https://www.ncbi.nlm.nih.gov/geo/>). scRNA‐seq raw data were obtained from Liao et al. ([2020](#mgg31442-bib-0014){ref-type="ref"}) (GSE131685), containing 23,366 high‐quality cells from three normal human kidney samples.

2.3. scRNA‐seq data processing and quality control {#mgg31442-sec-0009}
--------------------------------------------------

Whole process was performed under R (version 3.6.2) and the raw data of gene expression matrix was converted into Seurat object via the Seurat package of R (version 3.1.3). Average was acquired in the situation of duplicated gene expressions and low‐quality cells which had either expressed genes less than 200 or higher than 2500, or mitochondrial gene expression exceeded 30% were excluded for following analysis. Then, we visualized the relationships between the percentage of mitochondrial genes and mRNA reads, and between the number of mRNAs and the reads of mRNA. After that, remaining gene expression matrices were normalized and top 2,000 variable genes were selected for downstream analysis.

2.4. Principal component analysis (PCA) and dimensional reduction {#mgg31442-sec-0010}
-----------------------------------------------------------------

Seurat *CellCycleScoring* function was administered to diminish the error in cell clustering since different phases of cell may interfere the following procedure and cell clustering results. All data were scaled to weight for downstream analysis and *RunPCA* function was used to determine PCs. By the visualization of JackStraw plot and Elbow plot, top 20 PCs were selected, and *RunHarmony* was adopted to eliminating batch effect as much as possible. *RunUMAP* as well as *FindNeighbors* function with harmony reduction was chosen and *FindClusters* with resolution of 0.25 was performed to identify different clusters.

2.5. Annotation of clusters and identification of ACE2 expression {#mgg31442-sec-0011}
-----------------------------------------------------------------

Marker genes were found via *FindAllMarkers* function with threshold of 0.25 and annotation was performed based on the canonical marker genes provided by previous studies (Chabardès‐Garonne et al., [2003](#mgg31442-bib-0001){ref-type="ref"}; Chen, Cheung, Shi, Zhou, & Lu, [2018](#mgg31442-bib-0004){ref-type="ref"}; Habuka et al., [2014](#mgg31442-bib-0009){ref-type="ref"}; Lee, Chou, & Knepper, [2015](#mgg31442-bib-0013){ref-type="ref"}; Nakagawa et al., [2002](#mgg31442-bib-0017){ref-type="ref"}; Park et al., [2018](#mgg31442-bib-0020){ref-type="ref"}; Shankland, Smeets, Pippin, & Moeller, [2014](#mgg31442-bib-0022){ref-type="ref"}; Young et al., [2018](#mgg31442-bib-0032){ref-type="ref"}). After cell type identification, violin plot as well as feature plot were visualized to identify the *ACE2* expression in each cluster. Also, human protein atlas of *ACE2* was accessed in order to acquire more evidence ascertaining the expression level of *ACE2* in kidney cells (<https://www.proteinatlas.org/>). In addition, co‐expression analysis was performed with normalized cluster matrices data. Pearson\'s correlation test was administered between each gene in single‐cell transcriptome and *ACE2*. Significantly top 200 *ACE2* co‐expressed genes (*p* value \<0.05) were collected for following downstream Gene Ontology (GO) as well as Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis (*p* value \<0.05), with the corresponding databases of Carlson M (2019). *org*.*Hs*.*eg*.*db*, and *STRINGI*, respectively.

3. RESULTS {#mgg31442-sec-0012}
==========

3.1. Identification of cell types {#mgg31442-sec-0013}
---------------------------------

After quality control and data normalization among three human kidney samples (baseline characteristics of three samples are documented in Table [S1](#mgg31442-sup-0003){ref-type="supplementary-material"}) (Liao et al., [2020](#mgg31442-bib-0014){ref-type="ref"}), a total of 17,528 RNA features and 23,367 cells were retained for downstream analysis (detail of initial sequencing data is shown in Figure [S1](#mgg31442-sup-0001){ref-type="supplementary-material"}). Uniform Manifold Approximation and Projection (UMAP) was used for dimensional reduction for 23,367 high‐quality cells and 10 different clusters were obtained eventually (Figure [1a](#mgg31442-fig-0001){ref-type="fig"}). In order to reduce interference of cell clustering due to diverse phase in a cell cycle, *CellCycleScoring* function was used and visualization of no bias induced by cell cycle genes was observed (Figure [1b](#mgg31442-fig-0001){ref-type="fig"}). According to differential expressed genes in each cluster (Table [S2](#mgg31442-sup-0004){ref-type="supplementary-material"}) and canonical marker genes provided by Liao et al. (Table [S3](#mgg31442-sup-0005){ref-type="supplementary-material"}), 10 clusters were annotated as proximal convoluted tubule cells, proximal tubule cells, proximal straight tubule cells, glomerular parietal epithelial cells, NK‐T cells, monocytes, distal tubule cells, collecting duct principal cells, B cells, and collecting duct intercalated cells, respectively.

![Results from scRNA‐seq analysis. (a) Uniform manifold approximation and projection (UMAP) plot of samples revealing the different clusters of renal cells. (b) UMAP plot indicating different cluster with demonstration of different cell cycles. (c) Expression of ACE2 in different clusters of cells. (d) Violin plot showing the ACE2 expression in different clusters of cells. scRNA, single‐cell RNA sequencing](MGG3-9999-e1442-g001){#mgg31442-fig-0001}

3.2. Specific expression of ACE2 {#mgg31442-sec-0014}
--------------------------------

*ACE2* expression level in each cluster was identified by violin plot as well as scatter plot with reduction of UMAP, revealing that *ACE2* was predominantly expressed in proximal convoluted tubule cells, proximal tubule cells, proximal straight tubule cells, and glomerular parietal epithelial cells, respectively (Figure [1c,d](#mgg31442-fig-0001){ref-type="fig"}). The human protein atlas of *ACE2* in kidney cells indicated that a majority of *ACE2* expression located in proximal convoluted and straight cells (Figure [2](#mgg31442-fig-0002){ref-type="fig"}). As we discussed in introduction, SARS‐Cov‐2 entered human body via *ACE2*‐related pathway using cellular protease TMPRSS2 for priming (Hoffmann et al., [2020](#mgg31442-bib-0010){ref-type="ref"}). We additionally determined the expressing level of *TMPRSS2* in each cell cluster and, it was mainly expressed in cluster one to four and seven to eight (Figure [S2](#mgg31442-sup-0002){ref-type="supplementary-material"}), which are proximal convoluted tubule, proximal tubule, proximal straight tubule cells and glomerular parietal epithelial cells, distal tubule cells, and collecting duct principal cells, respectively. Therefore, with the intersection of ACE2 expressing level in each cell clusters and corroborative evidence from human protein atlas of ACE2, it furtherly provided substantial evidence to ascertain the potential entry pathway of SARS‐Cov‐2 by invading proximal tubule cells as well as glomerular parietal epithelial cells and, it gave a latent theory of SARS‐Cov‐2 replicating within these cells by using cellular protease TMPRSS2 for priming.

![Human protein atlas showing the expression level of ACE2. (Shade of brown indicates the expression level: darker indicates high‐level expression and lighter indicates low level expression)](MGG3-9999-e1442-g002){#mgg31442-fig-0002}

3.3. GO & KEGG analysis of ACE2 co‐expression genes {#mgg31442-sec-0015}
---------------------------------------------------

Pearson\'s correlation test was administered between *ACE2* and cluster one to four to obtain significantly positive or negative co‐expressed genes (*p* value \<0.05). Top 200 positive and negative co‐expressed genes (top 50 is listed in Table [1](#mgg31442-tbl-0001){ref-type="table"}) were selected to downstream GO and KEGG analysis (Complete *ACE2* co‐expressed genes are documented in Table [S4](#mgg31442-sup-0006){ref-type="supplementary-material"}).

###### 

Positive and negative co‐expression gene of ACE2

  Cluster 1 (+)   Cluster (−)   Cluster 2 (+)   Cluster 2 (−)   Cluster 3 (+)   Cluster 3 (−)   Cluster 4 (+)   Cluster 4(−)
  --------------- ------------- --------------- --------------- --------------- --------------- --------------- --------------
  TMBIM6          RPS29         MTRNR2L1        RPL21           FAM118A         GSTP1           GPRIN2          EIF1
  CLDN2           RPL21         PSAP            MT1H            THSD4           MT1E            SAPCD1‐AS1      HLA‐B
  DPEP1           RPS27         MTRNR2L10       RPL41           SLC22A7         TMSB10          GAB1            B2M
  NAT8            RPL41         MTRNR2L8        RPS27           GLYATL1         ACTG1           TTLL7           RPL18
  HSP90B1         RPL12         TMBIM6          RPS29           DCXR            KIFC3           STS             ARHGDIB
  SLC27A2         RPS26         EPCAM           RPL12           ABHD14A         NEAT1           MFSD2A          RPL4
  ITM2B           RPS4Y1        MTRNR2L6        RPL39           BTG2            ITGAV           EPDR1           TMSB4X
  MTRNR2L1        FXYD2         SLC3A1          MT1G            NRSN2‐AS1       CHMP4A          FARP2           RPS3
  SPINT2          MT1G          GAL3ST1         RPL26           ASPHD2          WFDC2           C9orf116        RPL41
  APOM            RPL26         CDH16           MT1F            NAT8            MYL6            LINC00526       HLA‐A
  CLTRN           MT1H          MTRNR2L11       ATP5F1E         MYH8            PTPN1           SPTBN4          EVL
  SLC22A6         UQCRQ         SLC27A2         POLR2L          CYP4A11         MBD4            SBSPON          TRBC2
  CYBA            S100A1        PTH1R           MT2A            AZGP1           POLR2J3         ENPP7           
  TMED10          UQCR11        GMFG            COX7C           MSRB1           SOX4            SH3BGRL2        
  GADD45A         RARRES3       APOM            RPS4Y1          PCK1            GPAT4           MGAM            
  STARD9          MIF           ATP1A1          IFITM3          MTRNR2L1        CGNL1           ST6GALNAC3      
  TPT1            FABP3         PLG             FXYD2           DEPDC1          LRRFIP1         NFASC           
  FOLR1           S100A11       ERRFI1          UBA52           F11‐AS1         IFITM3          KLHL29          
  RTN4            NDUFA13       SLC22A6         RPL31           RBP4            PPP1R14B        EMILIN1         
  SLC3A1          DAB2          BHMT            MT1E            GSTA2           PSMD12          TANC1           
  SLC13A3         SVIP          CYBA            RPS26           GSTA5           TAX1BP3         PLA2R1          
  CTBP1‐AS        RPL39         SLC22A11        NDUFB1          SMIM24          ABHD11          PARD3B          
  MTRNR2L8        ATP5ME        PCK1            UQCR11          CARMN           AC124319.1      COL4A3          
  CUBN            RPL31         AZGP1           MIR4458HG       ACVR1           RABIF           MYRIP           
  PSAP            PSME1         PCP2            TMSB10          AKR7A3          CITED4          TNNC1           
  SERPINI1        RPS8          CYP4F2          RPS2            MIOX            EPS15           RBP1            
  AQP1            SYF2          GRK4            RPS15A          RTN4            MIEN1           PLOD2           
  FAM151A         NDUFA1        ADAMTSL5        SKP1            MTRNR2L10       THBS1           APOD            
  GGH             PCP4          DDC             PPDPF           GPT             RDH11           BASP1           
  ATP1A1          POLR2L        FBXL6           PDCD5           GADD45A         ARHGAP35        SPOCK1          
  SLC6A19         RPL36A        CES2            RPLP2           ARHGAP24        GOLGA2          LRP11           
  SLC22A2         RPL37A        IWS1            APEX1           RGN             WDR83           MAGI2           
  C18orf54        ATP5MF        ATP6V0B         CCDC58          ARFGEF3         EXOSC7          BGN             
  SMIM24          COX7C         ADIRF           MACROD1         ALDH2           MBNL1           WT1             
  TMEM59          NDUFA3        MEPCE           SULT1A1         MPC1            BNC2            CDC42EP2        
  NACA2           OST4          PDIA3           NME1            ATP1B1          NKAIN4          ZNF385A         
  CDHR2           NIPSNAP2      ASAH1           IL32            SEC14L2         RNPC3           DCN             
  FN3K            MICOS10       MTRNR2L12       RPS19           EHMT2‐AS1       C3              RHBDF1          
  GOLGA8A         TOMM5         NAT8            MTLN            FMO5            EIF4A3          VASN            
  PLXNA3          HSPA1B        AGT             RPL19           GGH             YPEL3           ZNF423          
  AUP1            DCDC2         IRX5            RPS28           SLC39A5         SNX6            TPPP3           
  SLC3A2          OXT           ZNF786          RPL23A          TMEM176B        POLR2L          CA10            
  APOE            RPL17         PTN             PSMA2           CERCAM          ZSCAN16‐AS1     NPHS1           
  SARAF           WFDC2         ABHD14A         S100A1          RNF165          MT‐ND4          CLIP3           
  SPP1            ATP5MPL       SPINT2          CAPG            GC              ANXA4           CXADR           
  AZGP1           DYNC1I2       SEC23IP         AC026462.3      PLCH2           VPS35           UACA            
  CD63            MT1E          FN3K            EIF3J           ADIRF           BNIP2           CDK2AP1         
  AMN             AL359555.4    DHRS7B          PCP4            TEX51           RAB6A           PPP1R14C        
  MAGEE1          S100A10       ZBTB8A          NOB1            EPHA1‐AS1       MIR29B2CHG      HAAO            
  MTRNR2L10       RGS14         IMPDH1          ATP5ME          EXTL3‐AS1       PAFAH1B3        CDC42BPB        

Top 50 genes of each (Total co‐expression genes could be checked in supplementary file).

"+" indicates positive co‐expressed genes of ACE2.

"−" indicates negative co‐expressed genes of ACE2.
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Regarding to cluster 1, proximal convoluted tubule cells, material transportation processes (*e*.*g*.*CLN3 \[OMIM \#607042\]*,*SLC7A2 \[OMIM \#601872\]*,*SLC2A6 \[OMIM \#606813\]*,*NPC2 \[OMIM \#601015\]*), transportation‐related activity, and cellular components (*e*.*g*.*PCYOX1 \[OMIM \#610995\]*,*TIMM23B \[OMIM \#605034\]*,*SLC2A6*,*SLC9A3 \[OMIM \#182307\]*), and neutrophil‐mediated immunity (*e*.*g*.*METTL7A \[OMIM \#618338\]*,*DYNLL1 \[OMIM \#601562\]*,*S100P \[OMIM \#600614\]*,*CST3 \[OMIM \#604312\]*) were enriched in positive co‐expressed GO analysis (Figure [3a](#mgg31442-fig-0003){ref-type="fig"}) and, renin‐angiotensin system (RAS) was revealed significance in KEGG pathway analysis (Figure [3c](#mgg31442-fig-0003){ref-type="fig"}). For negative co‐expressed genes, viral transcription and expression, mRNA catabolic processes (*e*.*g*.*RPS29 \[OMIM \#603633\]*,*RPL21 \[OMIM \#603636\]*,*RPS27 \[OMIM \#603702\]*,*RPL41 \[OMIM \#613315\]*) were enriched in GO analysis (Figure [3b](#mgg31442-fig-0003){ref-type="fig"}), and ribosome as well as oxidative phosphorylation pathway were enriched in KEGG analysis (Figure [3d](#mgg31442-fig-0003){ref-type="fig"}).

![GO & KEGG analysis of cluster 1. (a) GO analysis of positive top 200 co‐expression genes of ACE2 in cluster 1. (b) GO analysis of negative co‐expression genes of ACE2 in cluster 1. (c) KEGG analysis of positive top 200 co‐expression genes of ACE2 in cluster 1. (d) KEGG analysis of negative top 200 co‐expression genes of ACE2 in cluster 1. GO, Gene Ontology](MGG3-9999-e1442-g003){#mgg31442-fig-0003}

In cluster 2, proximal tubule cells, except material transportation enriched biological processes as cluster 1, neutrophil activation, immune‐related responses and degranulation (*e*.*g*.*MLEC \[OMIM \#613802\]*,*CTSH \[OMIM \#116820\]*,*PRCP \[OMIM \#176785\]*,*UNC13D \[OMIM \#608897\]*) were enriched for positive co‐expression GO terms (Figure [4a](#mgg31442-fig-0004){ref-type="fig"}), and lysosome‐related pathway was shown in KEGG analysis (Figure [4c](#mgg31442-fig-0004){ref-type="fig"}). Contrarily, in negative co‐expression enrichment, viral gene transcription, expression, and translational initiation were dominant in GO analysis (*e*.*g*.*RPL21*,*RPL41*,*RPS27*,*RPS29*) (Figure [4b](#mgg31442-fig-0004){ref-type="fig"}), while in KEGG analysis, ribosome‐related pathway was enriched (Figure [4d](#mgg31442-fig-0004){ref-type="fig"}).

![GO & KEGG analysis of cluster 2. (a) GO analysis of positive top 200 co‐expression genes of ACE2 in cluster 2. (b) GO analysis of negative co‐expression genes of ACE2 in cluster 2. (c) KEGG analysis of positive top 200 co‐expression genes of ACE2 in cluster 2. (d) KEGG analysis of negative top 200 co‐expression genes of ACE2 in cluster 2. GO, Gene Ontology](MGG3-9999-e1442-g004){#mgg31442-fig-0004}

When it comes to proximal straight tubule cells of cluster 3, material catabolic and metabolic process (*e*.*g*.*AGXT2 \[OMIM \#612471\]*,*ASRGL1 \[OMIM \#609212\]*,*HPD \[OMIM \#609695\]*,*HYAL1 \[OMIM \#607071\]*) were predominantly enriched GO terms in top 200 positive co‐expressed genes (Figure [5a](#mgg31442-fig-0005){ref-type="fig"}) with peroxisome proliferators‐activated receptors (PPAR) signaling pathway KEGG analysis shown in Figure [5c](#mgg31442-fig-0005){ref-type="fig"}. Nevertheless, for negative co‐expressed genes, RNA‐related catabolic processes and regulation (*e*.*g*.*PSMD12 \[OMIM \#604450\]*,*EXOSC7 \[OMIM \#606488\]*,*EIF4A3 \[OMIM \#608546\]*,*PSMD13 \[OMIM \#603481\]*) were mainly enriched for GO terms (Figure [5b](#mgg31442-fig-0005){ref-type="fig"}) while there was no significant KEGG pathway could be obtained.

![GO & KEGG analysis of cluster 3. (a) GO analysis of positive top 200 co‐expression genes of ACE2 in cluster 3. (b) GO analysis of negative co‐expression genes of ACE2 in cluster 3. (c) KEGG analysis of positive top 200 co‐expression genes of ACE2 in cluster 3. (d) KEGG analysis of negative top 200 co‐expression genes of ACE2 in cluster 3. GO, Gene Ontology](MGG3-9999-e1442-g005){#mgg31442-fig-0005}

For glomerular parietal epithelial cells of cluster 4, renal cell differentiation, urogenital system development, and extracellular structure organization (*e*.*g*.*CDKN1C \[OMIM \#600856\]*,*BMP7 \[OMIM \#112267\]*,*MME \[OMIM \#120520\]*,*LAMA5 \[OMIM \#601033\]*)‐related GO terms were enriched among positive co‐expressed genes (Figure [6a](#mgg31442-fig-0006){ref-type="fig"}) and, protein digestion as well as absorption pathway were enriched for KEGG‐related analysis (Figure [6c](#mgg31442-fig-0006){ref-type="fig"}). Conversely, among negative co‐expressed genes GO analysis, translational‐related processes and antigen presentation processes (*e*.*g*.*EIF1 \[OMIM \#300186\]*,*RPL18 \[OMIM \#604179\]*,*HLA*‐*B \[OMIM \#142830\]*,*B2 M \[OMIM \#109700\]*,*HLA*‐*A \[OMIM \#142800\]*) were enriched GO terms (Figure [6b](#mgg31442-fig-0006){ref-type="fig"}), while ribosome and viral infection‐related pathways were enriched in KEGG analysis (Figure [6d](#mgg31442-fig-0006){ref-type="fig"}).

![GO & KEGG analysis of cluster 4. (a) GO analysis of positive top 200 co‐expression genes of ACE2 in cluster 4. (b) GO analysis of negative co‐expression genes of ACE2 in cluster 4. (c) KEGG analysis of positive top 200 co‐expression genes of ACE2 in cluster 4. (d) KEGG analysis of negative top 200 co‐expression genes of ACE2 in cluster 4. GO, Gene Ontology](MGG3-9999-e1442-g006){#mgg31442-fig-0006}

4. DISCUSSION {#mgg31442-sec-0016}
=============

According to previous study (Chiu, [2003](#mgg31442-bib-0006){ref-type="ref"}; Yeung et al., [2016](#mgg31442-bib-0031){ref-type="ref"}), two categories of coronavirus, SARS‐CoV and MERS‐CoV had been reported to damaged kidney through immunocompromise and induced apoptosis of renal cells. Although the exact evidence for kidney injury caused by COVID‐19 has not been estimated, several infected patients' studies revealed the potential risk of kidney vulnerable to be damaged due to SARS‐Cov‐2 virus direct effect. Wang et al. ([2020](#mgg31442-bib-0028){ref-type="ref"}) reported five AKI cases in total of 138 patients, Huang et al. ([2020](#mgg31442-bib-0011){ref-type="ref"}) reported three AKI cases which were all in intensive condition, Guan et al. ([2020](#mgg31442-bib-0008){ref-type="ref"}) reported six AKI patients among total of 1,099 patients, and three patients with creatinine level greater than 133 μmol/L, indicating suspecting kidney injury, in total of 62 patients outside Wuhan were reported by Xu et al. ([2020](#mgg31442-bib-0030){ref-type="ref"}). Hypothesis of virus direct effect resulting in kidney damage was suspected within the abovementioned case‐studies and, more importantly, based on our study results of scRNA‐seq in human kidney, potential route for COVID‐19 leading kidney damage via *ACE2* was estimated.

*ACE2* participates in the synthesis and catabolism of Ang II that induces inflammation, cell growth, mitogenesis, apoptosis, and regulates the gene expression of bioactive substances, all of which might exacerbate to renal tissue injury. Moreover, ACE2 inhibition was reported to be associated with increasing albumin excretion and worsen glomerular injury (Soler, Wysocki, & Batlle, [2008](#mgg31442-bib-0026){ref-type="ref"}), which was confirmed by an experimental study using exogenous human recombinant *ACE2* to slow the progression of chronic kidney disease by reducing in albumin excretion (Oudit et al., [2010](#mgg31442-bib-0019){ref-type="ref"}). As we known, catabolism of Ang II to produce Ang 1--7 is the main function of *ACE2*, while renal damage or disorder may happen with increasing Ang II (Ruiz‐Ortega et al., [2006](#mgg31442-bib-0021){ref-type="ref"}). Thus, the imbalance expression level of *ACE2* accelerates the renal damage.

Furthermore, RAS could be a potential pathway influencing on renal injury progression via mitogen‐active protein kinase (MAPK)‐mediated apoptosis, NF‐κB‐mediated inflammation, and redox imbalance promoting oxidative stress (Gnudi, Coward, & Long, [2016](#mgg31442-bib-0007){ref-type="ref"}; Newsholme, Cruzat, Keane, Carlessi, & de Bittencourt, [2016](#mgg31442-bib-0018){ref-type="ref"}; Sharma, Anders, & Gaikwad, [2019](#mgg31442-bib-0023){ref-type="ref"}). A literature speculated that compromised kidney perfusion and altered intrarenal hemodynamics balance attributed to systemic and intrarenal RAS activation may be the critical pathogenic factors (Matejovic et al., [2016](#mgg31442-bib-0015){ref-type="ref"}). From our GO & KEGG analysis, RAS was a significant pathway in *ACE2* co‐expressed gene enrichment, which might indicate one of the potential mechanisms of COVID‐19 damage to kidney. Interestingly, neutrophil‐mediated immunity was detected in almost positive co‐expressed genes analysis. SARS‐Cov‐2 invasion to kidney via *ACE2* may interfere immunity response, which was a underlying mechanism similar to SARS‐CoV damage to kidney by immunocompromise (Chiu, [2003](#mgg31442-bib-0006){ref-type="ref"}). Glomerulus was also a potential target for SARS‐Cov‐2 according to our scRNA‐seq data, and the GO enrichment of glomerulus was associated with development, such as glomerulus development, nephron development, even though kidney development, which may be a pathogenic factor for the exacerbation of patient kidney\'s status.

To the best of our knowledge, no specific medication could be used to against COVID‐19 but symptomatic treatment would be the predominant strategy. Occurrence of AKI is the most frequent renal‐related complication in COVID‐19 patients, which increases the risk factor for mortality. From above discussion, dealing with *ACE2* expression imbalance and RAS activation would be the main issues. Recombinant *ACE2* was reported to be effective in slowing the progression of kidney disease by reducing albumin excretion and modulating RAS depressor arm (*AT2R*, *ACE2*, Ang 1--7) by *ACE2* activator or *AT2R* agonist might protect the kidney from renal injury (Oudit et al., [2010](#mgg31442-bib-0019){ref-type="ref"}; Sharma, Malek, Mulay, & Gaikwad, [2019](#mgg31442-bib-0024){ref-type="ref"}), which may provide potential clues for clinicians encountering COVID‐19 patients, especially complicated with kidney injury. However, the abovementioned mechanism of kidney injury in COVID‐19 infection should be verified in experiment under precise experimental design.

5. CONCLUSION {#mgg31442-sec-0017}
=============

This study speculated that SARS‐Cov‐2 invaded proximal convoluted tubule, proximal tubule, proximal straight tubule cells, and glomerular parietal epithelial cells by means of *ACE2* receptor and damaging kidney tissue through *ACE2* imbalance and RAS activation, which offers substantial clues for clinical practice dealing with renal‐related complications caused by COVID‐19.
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